{
    "eid": "2-s2.0-85137915823",
    "title": "Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Agricultural and Biological Sciences (all)",
            "@code": "1100",
            "@abbrev": "AGRI"
        },
        {
            "@_fa": "true",
            "$": "Biochemistry, Genetics and Molecular Biology (all)",
            "@code": "1300",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Biomarkers",
        "CAR T cell",
        "chimeric antigen receptor T cell",
        "hematologic malignancy"
    ],
    "authors": [
        "Kitsada Wudhikarn",
        "Ana Alarc\u00f3n Tom\u00e1s",
        "Miguel Angel Perales",
        "Kazunori Murata"
    ],
    "citedby-count": 0,
    "ref-count": 97,
    "ref-list": [
        "CAR T cell immunotherapy for human cancer",
        "FDA approves first BCMA-targeted CAR-T cell therapy",
        "Idecabtagene vicleucel in relapsed and refractory multiple myeloma",
        "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma",
        "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma",
        "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study",
        "Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)",
        "KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma",
        "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study",
        "Toxicities of chimeric antigen receptor T cells: recognition and management",
        "Clinical manufacturing of CAR T cells: foundation of a promising therapy",
        "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial",
        "Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy",
        "Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas",
        "Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) vs standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma",
        "Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study",
        "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia",
        "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia",
        "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial",
        "KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results",
        "KTE-X19 active in MCL",
        "Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib",
        "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia",
        "Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL",
        "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma",
        "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium",
        "Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma",
        "Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma",
        "Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia",
        "T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade",
        "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells",
        "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia",
        "Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management",
        "Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)",
        "How I treat adverse effects of CAR-T cell therapy",
        "Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities",
        "Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management",
        "Beyond the storm \u2013 subacute toxicities and late effects in children receiving CAR T cells",
        "Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers",
        "Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults",
        "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy",
        "Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia",
        "Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells",
        "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients",
        "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells",
        "Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia",
        "Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL",
        "Impact of disease burden on long-term outcome of 19\u201328z CAR modified T cells in adult patients with relapsed B-ALL",
        "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells",
        "Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel",
        "Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas",
        "Cytokine multiplex analysis",
        "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy",
        "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells",
        "Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma",
        "Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia",
        "Early and late hematologic toxicity following CD19 CAR-T cells",
        "Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies",
        "CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma",
        "Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature",
        "Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)",
        "Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults: a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)",
        "Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T-cells",
        "EASIX in patients with acute graft-vs-host disease: a retrospective cohort analysis",
        "Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells",
        "CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity",
        "Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy",
        "Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels",
        "High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in vivo CAR T-cell kinetics",
        "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells",
        "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia",
        "Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy",
        "Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma",
        "TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance",
        "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo",
        "T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma",
        "Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies",
        "Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)",
        "CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial",
        "Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)",
        "Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL",
        "Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response",
        "Gut microbiota in cancer immune response and immunotherapy",
        "Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy",
        "Befriending the hostile tumor microenvironment in CAR T-cell therapy",
        "Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment",
        "Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response",
        "Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia",
        "Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy",
        "Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients",
        "Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas",
        "High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma",
        "Prognostic impact of 18F-FDG PET/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells",
        "Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity",
        "CAR T-cell therapy in large B-cell lymphoma",
        "The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Murcia",
            "@id": "60000130",
            "affilname": "Universidad de Murcia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000130",
            "affiliation-country": "Spain"
        }
    ],
    "funding": []
}